News|Articles|May 13, 2014

KBI Biopharma Acquires Merck's Biologics Operations

Author(s)Pharmaceutical Technology Editors

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

KBI Biopharma (KBI), a contract development and manufacturing organization, has signed an agreement with Merck & Co., to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014. Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third-party customers.

KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.

Source: KBI Biopharma

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.